Analysis of circulating tumor DNA (ctDNA) identifies on-treatment genomic alterations in a phase 2 study of veliparib plus FOLFIRI ± bevacizumab vs. placebo plus FOLFIRI ± bevacizumab in metastatic colorectal cancer (mCRC)

被引：0
|
作者：
Ramathal, Cyril Y. [1 ]
Murphy, Erin [1 ]
Asque, Elizabeth [1 ]
Grundstad, Arne Jason [1 ]
Ansell, Peter [1 ]
He, Lei [1 ]
Luo, Yan [1 ]
Berlin, Jordan [2 ]
Waring, Jeff [1 ]
机构：
[1] Abbvie, N Chicago, IL USA
[2] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-4461
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4461
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
    Gorbunova, Vera
    Beck, J. Thaddeus
    Hofheinz, Ralf-Dieter
    Garcia-Alfonso, Pilar
    Nechaeva, Marina
    Gracian, Antonio Cubillo
    Mangel, Laszlo
    Fernandez, Elena Elez
    Deming, Dustin A.
    Ramanathan, Ramesh K.
    Torres, Alison H.
    Sullivan, Danielle
    Luo, Yan
    Berlin, Jordan D.
    BRITISH JOURNAL OF CANCER, 2019, 120 (02) : 183 - 189
  • [2] A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
    Vera Gorbunova
    J. Thaddeus Beck
    Ralf-Dieter Hofheinz
    Pilar Garcia-Alfonso
    Marina Nechaeva
    Antonio Cubillo Gracian
    Laszlo Mangel
    Elena Elez Fernandez
    Dustin A. Deming
    Ramesh K. Ramanathan
    Alison H. Torres
    Danielle Sullivan
    Yan Luo
    Jordan D. Berlin
    British Journal of Cancer, 2019, 120 : 183 - 189
  • [3] Phase 2 study of veliparib plus FOLFIRI ± bevacizumab versus placebo plus FOLFIRI ± bevacizumab in metastatic colorectal cancer.
    Gorbunova, Vera
    Beck, Thaddeus
    Hofheinz, Ralf
    Garcia-Alfonso, Pilar
    Nechaeva, Marina
    Gracian, Antonio Cubillo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
    Vera Gorbunova
    J. Thaddeus Beck
    Ralf-Dieter Hofheinz
    Pilar Garcia-Alfonso
    Marina Nechaeva
    Antonio Cubillo Gracian
    Laszlo Mangel
    Elena Elez Fernandez
    Dustin A. Deming
    Ramesh K. Ramanathan
    Alison H. Torres
    Danielle Sullivan
    Yan Luo
    Jordan D. Berlin
    British Journal of Cancer, 2019, 121 : 429 - 430
  • [5] A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer (vol 120, pg 183, 2019)
    Gorbunova, Vera
    Beck, J. Thaddeus
    Hofheinz, Ralf-Dieter
    Garcia-Alfonso, Pilar
    Nechaeva, Marina
    Gracian, Antonio Cubillo
    Mangel, Laszlo
    Fernandez, Elena Elez
    Deming, Dustin A.
    Ramanathan, Ramesh K.
    Torres, Alison H.
    Sullivan, Danielle
    Luo, Yan
    Berlin, Jordan D.
    BRITISH JOURNAL OF CANCER, 2019, 121 (05) : 429 - 430
  • [6] CAPIRI plus bevacizumab (CAPIRI-B) versus FOLFIRI plus bevacizumab (FOLFIRI-B) for the treatment of patients with metastatic colorectal cancer (mCRC).
    Ziras, N.
    Polyzos, A.
    Xenidis, N.
    Kalykaki, A.
    Androulakis, N. E.
    Papakotoulas, P.
    Kentepozidis, N. K.
    Makrantonakis, P.
    Xynogalos, S.
    Sougklakos, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [7] A comparison of efficacy of first-line chemotherapy regimens for metastatic colorectal cancer (mCRC): FOLFIRI plus bevacizumab vs. XELIRI plus bevacizumab
    Ocvirk, J.
    Rebersek, M.
    Boc, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 336 - 336
  • [8] Capecitabine plus bevacizumab (Cape-Bev) as a maintenance treatment after induction treatment with FOLFIRI plus bevacizumab (FOLFIRI-Bev) in metastatic colorectal cancer (mCRC).
    Tatli, Ali Murat
    Coskun, Hasan Senol
    Uysal, Mukremin
    Goksu, Sema Sezgin
    Arslan, Deniz
    Gunduz, Seyda
    Ozdogan, Mustafa
    Bozcuk, Hakan Sat
    Savas, Burhan
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] ABT-165 plus FOLFIRI vs bevacizumab plus FOLFIRI in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bevacizumab - Trial in progress
    Wainberg, Z.
    Wang, L.
    Yue, H.
    Motwani, M.
    Kasichayanula, S.
    Blaney, M.
    Naumovski, L.
    Strickler, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [10] ABT-165 plus FOLFIRI versus bevacizumab plus FOLFIRI in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bevacizumab.
    Wainberg, Zev A.
    Wang, Lan
    Yue, Huibin
    Motwani, Monica
    Kasichayanula, Sreeneeranj
    Blaney, Martha Elizabeth
    Naumovski, Louie
    Strickler, John H.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
12345